British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread ...
Bachem, a leading partner in peptide and oligonucleotide manufacturing, today announced progress in its plans to expand capacity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback